Program
toripalimab
Also written as “Toripalimab”, “Toripalimab Injection” and “CM082 plus JS001”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma · Stomach Neoplasms · Carcinoma, Transitional Cell, led by 5 companies.
Drug pageToripalimab: every studyMany companies study it; this page follows only the 13 they lead. All 362 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 54 open or running | phase 2since Mar 17, 2022 | Mar 17, 2022 | none ahead |
| Mabwell (Shanghai) Bioscienceits history only | 33 open or running | phase 3since Sep 9, 2024 | Sep 25, 2023 | Dec 31, 2026phase 2 · NCT06079112 |
| Coherus Oncologyits history only | 22 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| Suzhou Zelgen Biopharmaceuticalsits history only | 21 open or running | phase 2since Aug 3, 2020 | Aug 3, 2020 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 3since Dec 12, 2018 | Dec 12, 2018 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of RemeGen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named toripalimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JS001
- Mar 17, 2022First study: phase 2 study in Muscle Invasive Bladder CarcinomaFirst studyNCT05297552 · 40 planned · China
- Sep 1, 2023Phase 2 study in Advanced Solid TumorNCT06038396 · 48 planned · China
- Oct 23, 2023Phase 2 study in Breast NeoplasmsNCT06105008 · China
- Nov 23, 2023Phase 2 study in Stomach NeoplasmsNCT06155383 · 90 planned · China
- Jan 17, 2024Phase 2 study in Breast NeoplasmsNCT06227117 · 120 planned · China
TargetBeta
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 5 RemeGen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06227117Breast Neoplasms · China | 2 | Recruiting | Dec 2025 | 120 |
| NCT06155383Stomach Neoplasms · China | 2 | Recruiting | Jan 31, 2025 | 90 |
| NCT06105008Breast Neoplasms · China | 2 | Withdrawn | Dec 20, 2025 | 0 |
| NCT06038396Advanced Solid Tumor · China | 2 | Recruiting | Feb 28, 2026 | 48 |
| NCT05297552Muscle Invasive Bladder Carcinoma · China | 2 | Recruiting | Jun 1, 2024 | 40 |
How it is read
Names in the registry
- “Toripalimab”, 14 entries
- “Toripalimab Injection”, 3 entries
- “CM082 plus JS001”, 3 entries
- “ABO2109 Injection;Toripalimab”, 2 entries
- “JS001”, 2 entries
Codes read as this program: JS001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Breast Neoplasms, 3 studies
- Melanoma, 3 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Transitional Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.